M15: Antivirals Flashcards

1
Q

Human Herpes Viruses (5)

A

HSV: Herpes Simplex virus

CMV: Cytomegalovirus

EBV: Epstein Barr virus

VZV: Varicella Zoster virus

HHV-8: Human Herpes virus 8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Associated Diseases of Human Herpes Viruses:

HSV: Herpes Simplex virus

CMV: Cytomegalovirus

EBV: Epstein Barr virus

VZV: Varicella Zoster virus

HHV-8: Human Herpes virus 8

A

Fever blisters, genital herpes, encephalitis

Retinitis, colitis, pneumonia

Mononucleosis, lymphoma

Chickenpox, shingles

Kaposi sarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Associated Diseases of Other Viruses:

HAV: Hepatitis A virus

HBV: Hepatitis B virus

HCV: Hepatitis C virus

HPV: Human Papilloma virus

Influenza A and B

RSV: Respiratory Syncytial virus

HIV

Lassavirus

Enterovirus

A

Food-borne hepatitis A

Blood-borne hepatitis B

Blood-borne hepatitis C

Warts, cervical/anal cancer

Influenza

Bronchitis, pneumonia

AIDS

Lassa fever

Diarrhea, meningitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Drugs that Treat Viral Diseases:

1) HSV
2) CMV
3) VZV
4) RSV
5) HBV
6) HCV
7) Influenza A
8) Influenza B
9) Lassavirus
10) Enterovirus
11) HPV

A

1) *(val)acyclovir, famciclovir, penciclovir, *foscarnet
2) *(val)ganciclovir, *foscarnet, cidofovir
3) *(val)acyclovir, famciclovir
4) *ribavirin, pavilizumab
5) *tenofovir, *emtricitabine, *lamivudine, entecavir, telbivudine, *adefovir
6) *interferon-α, *ribavirin, *telaprevir, *boceprevir, *sofosbuvir, *simeprevir
7) *amantadine, *rimantadine, *oseltamivir, *zanamivir
8) *oseltamivir, *zanamivir
9) *ribavirin
10) pleconaril
11) imiquimod, interferon-α

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Immediately lethal viral infections:

Some viral diseases are immediately lethal and these are relatively (common / rare).

However, these outbreaks receive a lot of media attention, often out of proportion to the numbers of humans affected.

These viruses cause intense _ and patients die from _ or _.

Examples: (3)

A

rare

vascular inflammation
hemorrhage or pulmonary edema

Ebola, Yellow Fever, Hanta viruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Self limited viral infections:

(Most / Few) viral diseases are self-limited; they cause an illness but then the host develops _ and eradicates the virus through _ and _ response.

a. The immunity can protect the host from re-infection _
Example: _

b. Immunity can be only for a _ duration while decreasing the severity of subsequent infections due to some remaining immunity
Example: _.

c. Some viruses can _ the acquired immunity of the host by changing the antigenic properties of its _
Example: _

A

Most
immunity
cytotoxic T cells and B cells

life-long
Hepatitis A

short
RSV

overcome
envelope
Influenza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Contained viral infections:

Many viral diseases are _ by the immune system, but are not _. These viruses establish themselves in the host.

a. Chronic persistent infection:

Some viruses cause a chronic persistent infection with _.

• Examples: Hepatitis C can cause _. HIV causes _.

b. Latent infection:

Other viruses remain latent and can _.

Most humans get infected with most of the human _ viruses before adulthood (HSV, VZV, CMV, EBV, HHV-6, HHV-7).

The primary illness is often _ although may not be recognized.

The viruses establish themselves and remain quiescent unless they reactivate spontaneously, due to _ or when the host gets profoundly _.

• Example: _ is caused by primary infection with varicella zoster virus (VZV), dermatomal reactivation can occur later in life in the form of _.

A

contained
eradicated

ongoing replication
liver cirrhosis
CD4 lymphocyte destruction

replicate during stress or immunosuppressive states

herpes

symptomatic

inflammation
immunosuppressed

Varicella (chickenpox)
zoster (shingles)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Immunization:
Active immunization-Vaccines:

Active immunization with a vaccine elicits an immune response by _ and/or _.

These may protect the host from infection when it encounters the virus for the _ time.

The immunity is often _ as long as the virus does not change its antigenic coat. There are 2 types of vaccines (2)

A

T-cells (cytotoxic T-cells) and/or neutralizing antibodies by B-cells

first

long-lasting

attenuated
inactivated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Immunization:
Passive immunization- Immunolobulin (Ig):

Passive immunization can protect the host from infection by receiving _ derived from _.

These preparations often contain a minimum titer of _ to be protective for specific viruses.

They neutralize the virus and block its infectivity by prohibiting _.

It (does / does not) elicit any immune response from the host and due to the (long / short) half-life of immunoglobulins (~2 weeks) the protection (is / is not) long lasting.

Recent advances in purification and sterilization made these products much safer than in the past. However, due to shortages and expense they are not widely used.

A

immunoglobulins
human serum

IgG

viral entry into cells

does not
short
is not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Principles of antiviral therapy:
Virucides:

These are agents that _

Examples (4)

They have a limited use in _ infections, warts (destroying host tissues and virus). Potential use in transmission prevention.

A

directly inactivate intact viral particles.

detergents, organic solvents, UV light, photodynamic inactivation.

mucocutaneous HSV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Principles of antiviral therapy:
Immunomodulation:

In some instances we can _ the host immune response to better contain or eradicate the virus infection.

a. Inducing host factors with antiviral properties:

Such as _ (cytokine) and _ (cytokine inducer).

They induce degradation of _, inhibit viral _, and enhance _ and _ cells activity.

b. Restoring host immunity:

In specific cases we can restore the host immune response by decreasing _ or treating the cause of the _ state.

Examples: A renal transplant patient may develop post-transplant lymphoproliferative disease (PTLD) from the reactivation of _ due to the immunosuppressed state.

By decreasing his immunosuppressant agents the host can now _ this reactivation but as a consequence may _.

In AIDS patients presenting with _ (HHV-8 or KSHV) we can treat this by starting the patient on antiretrovirals for HIV. The increasing _ count causes regression of the lesions.

A

stimulate

interferon
imiquimod

viral RNA
protein synthesis
cytotoxic T lymphocytes (CTL) and natural killer (NK)

immunosuppressant medications
immunosuppressed

EBV

contain
reject the kidney transplant

Kaposi sarcoma
CD4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Principles of antiviral therapy:
Antivirals:

These drugs inhibit viral replication at the _ level and they have a restricted spectrum of activity.

They target virus-specific proteins and have (high / low) affinity for host encoded proteins.

For example, acyclovir requires the viral enzyme _ for phosphorylation into its active form. This phosphorylation cannot take place in _ host cells

a. Antiviral drugs act only on _ viruses. Those viruses that are in a _ phase are not using their polymerase enzyme and therefore not susceptible to _. Active HSV replication (genital herpes) can be treated with this antiviral, but the latent HSV in the ganglion cells will not be affected.

b. They are often used too _ to make an impact. By the time patients are _ from the viral infection, billions of host cells have already been infected and several billions of viral particles have been produced.
• Example: _ for influenza is only effective within the first 48 hours of symptoms

c. Rapid development of drug resistance. The high replication rates of viruses require “_” polymerases that work very _ but are not _. Many _ mutations occur and most affect the infectivity. However, some mutations enable the virus to select for medication _. Drug resistane should be suspected when there is lack of clinical and virological response to therapy.

A

cellular

low

thymidine kinase (TK)
uninfected 

replicating
quiescent
acyclovir

late
symptomatic
oseltamivir

sloppy
fast 
precise
spontaneous 
resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:

a. Nucleoside analogues:

They prevent viral replication by directly inhibiting the _ and by incorporating a faulty _ causing termination of growing RNA or DNA chain.
- Antivirals: (4).

b. Nucleotide analogues:

They prevent viral replication by directly inhibiting the _ and by incorporating a faulty _ causing termination of growing RNA or DNA chain.
- Antiviral: (1)

c. Pyrophosphate analogue:

Inhibits _
- Antiviral: (1)

A

viral DNA or RNA polymerase
nucleoside
Acyclovir, valacyclovir, ganciclovir, valganciclovir

viral DNA or RNA polymerase
nucleotide
Cidofovir

viral polymerase
Foscarnet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Acyclovir:

Mechanism of action:

Acyclovir (ACV) requires intracellular phosphorylation to _ which is the active drug.

The initial phosphorylation requires a viral kinase, called _, subsequent phosphorylations (2nd and 3rd step) by host cellular enzymes.

ACV-TP competitively inhibits _ and acts as a chain terminator due to absence of _.

Spectrum of activity:

_, _, and _ all of which encode the thymidine kinase.

However, there is a descending order of susceptibility (IC50); HSV-1>HSV-2>VZV) so _ or _ require higher doses.

It is important to note that the viral kinase produced by CMV has a very (high / low) affinity to acyclovir.

Extremely high doses of acyclovir would be required to halt the replication of _ thus acyclovir is not considered a drug of choice for infections due to _.

A

acyclovir-triphosphate (ACV-TP)

thymidine kinase (TK)

viral DNA polymerase
3’ hydroxyl group

HSV-1, HSV-2, and VZV

chickenpox or shingles

low

CMV
CMV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Acyclovir:

Clinical use:

a. First episode of orolabial herpes-treatment offers _ symptomatic benefit.
b. Recurrent orolabial herpes (fever blisters): _ benefit in symptoms.
c. First episode of genital herpes: _ benefit in regard to symptoms and healing
d. Recurrent genital herpes: Symptomatic therapy; _ benefit in symptoms. _ therapy (80% reduction of recurrences). Reduces subclinical of viral shedding and transmission (but only by 50%)
e. _ herpes (baby infected from mother)
f. Herpes encephalitis: _ therapy is associated with better outcomes
g. Varicella (chickenpox) in adults with rash

A

significant

only 1/2 day

significant

only 1 day
Suppressive

Neonatal

prompt

3

adults over 50 years

immunocompromised

Post organ transplantation prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Acyclovir:

Product availability:

The drug is available in (3). Oral bioavailability only 15-30% due to its large_ (liver).

The clinical use for PO acyclovir is mainly for _ and _ (HSV). The IV formulation is used for serious HSV such as _, _ infections and treatment of both _ and _ infections in immunocompromised patients

Adverse effects:

Acyclovir is generally very well tolerated but can cause _ due to precipitation of the drug in renal tubules especially if the patient is not well _.

It can rarely cause _ side effects especially in the setting of renal failure when drug levels are high.

Resistance:

There are two resistance mechanisms of HSV to acyclovir.

Most important is the reduced or absent _. The first _ step does not take place and no _ is being produced.

Another pathway to resistance develops when the viral DNA polymerase has decreased affinity for _. Resistant isolates emerge after prolonged acyclovir treatment in immunosuppressed patients.

These resistant isolates are cross-resistant to _, but still sensitive to _ and _.

A

a pill form, intravenous (IV) and topical
first-pass effect

oral and genital herpes
encephalitis
VZV
HSV and VZV

acute renal failure
hydrated

neurologic

thymidine kinase (TK)
phosphorylation
active drug

ACV-TP

ganciclovir
foscarnet and cidofovir

17
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Valacyclovir:

Mechanism of action:
It is an _ of acyclovir and is converted to ACV by first-pass intestinal and/or hepatic _. Same mechanism of action as acyclovir.

Drug availability:
Available in a _ form. Its bioavailability is 3 to 5-fold (higher / lower) and therefore can be taken less often than acyclovir

Clinical use:
It is used to treat _ and _ infections. It has a (more / less) convenient dosing regimen for HSV infections as opposed to acyclovir. It is also preferred for VZV infections (chickenpox or zoster) because of the (higher / lower) drug levels required (IC50).

A

oral pro-drug
hydrolysis

pill
higher

HSV and VZV
more
higher

18
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Ganciclovir:

Mechanism of action:
It is a _ analogue and requires intracellular phosphorylation by a viral kinase called _. It inhibits the viral polymerase and DNA synthesis.

Drug availability:
It can be administered (3). The oral bioavailability is 5-9%.

Clinical use:
Mainly _ disease in immunocompromised patients: AIDS (_, ), solid organ transplant and bone marrow transplant recipients with CMV infection (, syndrome or organ involvement).

Side effects:
Mainly (4)

Resistance:
After prolonged exposure to ganciclovir, mutations can occur on the _ kinase which will lead to ganciclovir resistance and in that case use of _ or _ is required.

A

nucleoside
UL97

PO, IV and intraocular

CMV
CMV retinitis, CMV colitis
CMV viremia

bone marrow suppression, headaches, fever, rash.

UL97 CMV
foscarnet or cidofovir

19
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Valganciclovir:

Mechanism of action:
It is a _ analogue and requires intracellular phosphorylation by a viral kinase called _. It inhibits the viral polymerase and DNA synthesis.

Drug availability:
It is available in a _ form only. It is the prodrug of _ with good bioavailability. After absorption the _ is removed during the first-pass through the liver and ganciclovir drug levels are similar to the IV administered formulation of ganciclovir.

Clinical use:
Mainly _ disease in immunocompromised patients: AIDS (_, ), solid organ transplant and bone marrow transplant recipients with CMV infection (, syndrome or organ involvement). It is the preferred agent for treatment of _ infections post transplantation. Also it is the preferred agent for _ in transplant recipients at risk for CMV infection or reactivation post transplantation

Side effects:
Mainly (4)

Resistance:
After prolonged exposure to ganciclovir, mutations can occur on the _ kinase which will lead to ganciclovir resistance and in that case use of _ or _ is required.

A

nucleoside
UL97

pill
ganciclovir
valine

CMV 
CMV retinitis, CMV colitis
CMV viremia
CMV 
CMV prophylaxis

bone marrow suppression, headaches, fever, rash.

UL97 CMV
foscarnet or cidofovir

20
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Cidofovir:

Mechanism of action:
It is a monophosphate _ analogue and requires phosphorylation by _ enzymes only to become a _ cidofovir which is the active form of the drug. Unlike nucleoside analogues such as acyclovir or ganciclovir, cidofovir does not require _ by a viral kinase.

Drug availability:
Available in the _ form

Clinical use:
Major use is for _ resistant CMV infections in organ transplant recipients. It is also used in treatment of _ viral infections (which causes hemorrhagic cystitis and or nephritis in renal transplant patients) and it may have activity against _

Side effects:
Mainly (3)

A

nucleotide
cellular
diphosphate
phosphorylation

IV

ganciclovir
BK
smallpox

nephrotoxicity, GI intolerance and neutropenia

21
Q

Mechanism of action of antivirals:
Antivirals for Herpes viruses:
Foscarnet:

Mechanism of action:
It is a _ analogue and inhibits the DNA polymerase of herpes viruses by reversibly blocking the _ (a necessary co-factor in the functioning of these enzymes). No _ is required for activity (not dependent on viral TK and requires no cellular phosphorylation).

Drug availability:
It can only be administered _.

Clinical use:
It has a broad antiviral spectrum against herpes viruses including (3). Mainly used in cases of HSV resistant to _ (TK deficient or mutation) and _ resistant CMV with UL97 mutation.

Side effects:
Major concern. It is directly toxic to _ leading to _ abnormalities (Ca, Mg, Phos, and K) and causes _ insufficiency. It can also cause _.

A

pyrophosphate
pyrophosphate binding site
metabolism

IV

HSV, CMV and VZV
acyclovir
ganciclovir

renal tubules
electrolyte
renal
penile ulcers

22
Q

Mechanism of action of antivirals:
Antivirals for influenza viruses:

Ion channel blockers:

The viral ion channel, _ channel, maintains the _ across the viral membrane during cell entry. As the virus enters the cell by endocytosis, _ occurs.

This low pH activates the M2 channel to bring _ into the virion core leading to its disintegration and the release of viral _ into the _.

M2 channel blockers will bind to the M2 channel and sterically _ it. This will block the protons from entering the virion which then does not _.

-The _: _ and _

Sialic acid analogues (neuraminidase inhibitors):

The sialic acid analogues block _ by competitively inhibiting the viral _. They are also called neuraminidase inhibitors.

A

M2
pH
endosomal acidification

protons
nucleocapsid
cytoplasm

blocking
disintegrate

adamantanes
Amantadine and Rimantadine

the release of new virions
neuraminidase

23
Q

Mechanism of action of antivirals:
Antivirals for influenza viruses:
Amantadine and Rimantadine:

Mechanism of action:
_ blockers.

Drug availability:
Both are available in _ and _

Clinical use:
Active against _ only. The M2 ion channel activity of influenza B is (higher / lower) than that of Influenza A to the point that it is completely _ to amantadine and rimantadine. They are effective if given _ in the course (within 36 hours). They also can be used for pre-exposure _ of influenza A (during flu season) or post-exposure _ (post contact).

Side effects:
They can cause reversible _ (dizziness, ataxia). This is more common with (amantadine / rimantadine) and especially seen in the _. Also they can cause _ and _.

Resistance:
Resistance can occur through mutations in the _ protein. It develops quickly in outbreaks and since 2006 most of the Influenza _ strains have been resistant.

A

Ion channel

capsules and liquid

Influenza A
higher 
insensitive 
early 
prophylaxis 
preemptive therapy

neurotoxicity
amantadine
elderly
nausea and dry mouth

M2
A

24
Q

Mechanism of action of antivirals:
Antivirals for influenza viruses:
Oseltamivir and Zanamivir:

Mechanism of action:
_ inhibitors.

Drug availability:
Oseltamivir is available in a _ form while zanamavir exists in a _ form and is administered via _.

Clinical use:
These drugs are used for treatment of infections with _ (including H1N1 and possibly avian influenza) and _. They can also be used as prophylaxis and preemptive therapy. They are usually active against strains resistant to _.

Side effects:
Oseltamivir can cause _ and _. Zanamivir can cause _ and _ in addition to nausea vomiting and diarrhea. Zanamavir should be used in caution in patients who have _ or _.

Resistance:
Resistance to oseltamivir occurs (more / less) frequently then resistance to the adamantanes. In these cases of oseltamivir resistant strains _ usually is still active.

A

Neuraminidase

pill
powder
inhalation

influenza A
B
adamantanes

nausea and vomiting
bronchospasm and cough
asthma or COPD

less
zanamavir

25
Q

Mechanism of action of antivirals:
Antivirals for viral hepatitis:

Antivirals for hepatitis C:
_: cytokine
_: inhibits viral RNA synthesis
Protease inhibitors: (4)

Antivirals for hepatitis B:
Nucleoside analogues: (4)
Nucleotide analogues: (2)

A

Interferon-α
Ribavirin
Telaprevir, boceprevir, sofosbuvir, simeprevir

Lamivudine, emtricitabine, entecavir, telbivudine
Tenofovir, adefovir

26
Q

Overview of viral hepatitis:

Hepatitis A
– _ transmission
– Self limited disease (hepatitis)
– Immunity?

Hepatitis B:
– Transmission by _
– _ hepatitis or _ hepatitis, cirrhosis, liver cancer
– _ transmission from mother to the newborn causes _ in majority of cases (80%)
– Adult infection is mainly _ (90%) but it causes _ or _ (10%) with subsequent risk of cirrhosis and hepatocellular carcinoma
– Immunity?

Hepatitis C:
– Transmission by _
– Adult infection causes _ (90%) with subsequent risk of cirrhosis and hepatocellular carcinoma.
– Immunity?

Hepatitis D:
– Transmitted by _
– _ virus, co-infection with _ required
– Exacerbates _ infection

Hepatitis E:
– _ transmission
– Self limited except for _ (high mortality 30%)
– Immunity?

A

Oral-fecal
vaccine, HAV-Ig

blood/semen
Self limited, chronic
Perinatal, chronic active hepatitis (CAH)
self limited, carrier state or chronic hepatitis
vaccine, HB-Ig

blood/semen
chronic hepatitis
No immunity and no vaccine available

blood
Defective, Hepatitis B
pre-existing chronic Hepatitis B

Oral-fecal
pregnant females
vaccine is being licensed

27
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):

There are six major genotypes numbered 1 to 6 identified for HCV.

Genotypes _ to _ are by far the most common in western countries.

Almost 75 % of HCV infections in the US are HCV genotype _. HCV genotype _ compromise approximately 15% of infections and genotype _ less than 10%.

Since late 1990’s, the standard treatment of HCV infection had been a combination of _ and _ for 24 weeks (for HCV genotype 2 or 3) or 48 weeks (for HCV genotype 1).

The major aim of treatment is to achieve a _ which is defined as undetectable HCV RNA at 24 weeks after completion of treatment.

Patients infected with HCV genotype _ only have a 50% response rate compared to 75% in patients with genotype _ and _.

Monotherapy with either ribavirin or interferon (is / is not) efficacious.

The majority of patients suffer from (mild / severe) side effects and many are unable to complete therapy.

A

1 to 4

1, 2, 3

pegylated interferon (PEG-IFN) 
ribavirin (RBV)

sustained virological response (SVR)

1
2 and 3

is not

severe

28
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):

_ against HCV are being developed.

In May, 2011 the FDA approved 2 first generation protease inhibitors (PI) _ and _.

Patients treated with one of those new agents in combination with _ and _ achieved higher SVR rates.

Recently in the fall of 2013 the FDA approved 2 second generation PI’s: _. The addition of second generation PI has led to achievement of SVR in up to 87% of patients infected with HCV genotype 1.

The addition of a PI to the standard regimen of _ and _ has become the new standard of care in the treatment of HCV infection.

(First / Second) generation agents are preferred over the (first / second) generation PI’s as they have a more favorable side effect profile and less drug-drug interaction.

A

Direct acting antivirals (DAA)

telaprevir and boceprevir

PEG-INF and RBV

simeprevir

PEG-IFN and ribavirin

Second
first

29
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Interferon-α:

Mechanism of action:
Is a cytokine with potent _ activity. After binding to receptors, interferon initiates a cascade of events that leads to various cellular responses such as inhibition of _, suppression of _, enhancement of the _ and augmentation of the specific _ of lymphocytes for target cells. _ have a longer half-life and are more effective.

Drug availability:
It is administered as _.

Clinical use:
HCV infection in combination with _, _.

Side effects: 
_ symptoms (malaise, myalgias, fever), _ symptoms (depression), _, _, _, and _.
A
immunomodulatory 
virus replication
cell proliferation
phagocytic activity of macrophages
cytotoxicity 
Pegylated formulations (PegIFN)

subcutaneous injections

ribavirin, papillomavirus infection (HPV)

Flu like
neuropsychiatric
bone marrow suppression, rash, alopecia and retinopathy

30
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Ribavirin:

Mechanism of action:
It is a synthetic _ analogue of guanine. The mechanism of action is not fully understood. It requires intracellular phosphorylation by _ enzymes. It decreases the _ and inhibits viral _.

Drug availability:
It is available as _, _, and _ formulations

Clinical use:
It is active against many _ viruses and used in treatment of HCV infection in combination with _. RSV infections in high-risk _ and _ patients (pneumonia). _ virus infection in West Africa.

Side effects: 
It causes (4).
A

nucleoside
host cellular
nucleotide pool
mRNA

PO, IV and inhaled

RNA
IFN-α
infants and immunocompromized
Lassa

hemolytic anemia, headaches, rashes and significant teratogenicity

31
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Protease inhibitors:

The HCV genome encodes a single _ that is ultimately cleaved into _.

Some of these smaller proteins are _ components of the virion and some are _ proteins required for ongoing viral replication.

NS3, a nonstructural viral protein and its cofactor NS4A form a _ that cleaves the HCV polyprotein into 4 structural and 6 nonstructural proteins.

Viral _ can initiate only after those proteins are cleaved.

NS3/4 Protease inhibitors will reversibly bind to the _ and inhibit HCV _.

_, cleaved from the polyprotein, is an RNA-dependent RNA polymerase.

NS5B inhibitors are _ analogue that inhibit the polymerase function halting HCV replication.

A

polyprotein
smaller proteins

structural 
nonstructural (NS)

heterodimer serine protease (NS3/4A)

replication

active site NS3/4A
replication

NS5B

nucleotide

32
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Protease inhibitors:

Virus binding and internalization

(a) ; cytoplasmic _ and _
(b) ; internal ribosome entry site (IRES) mediated _ and polyprotein _
(c) ; RNA _
(d) ; _ and _
(e) ; virion _ and _

HCV RNA replication occurs in a specific membrane alteration, the _.

A
release and uncoating 
translation, processing 
replication 
packaging and assembly
maturation and release

membranous web

33
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Boceprevir:

Mechanism of action:
_ generation _.

Drug availability:
Available _ three times daily.

Clinical use:
It is used in combination with _ and _ for treatment of naïve and treatment experienced patients infected with HCV genotype _.

Side effects:
(5). Multiple drug-drug interactions.

Resistance:
(High / Low) barrier for resistance thus they need to be used in combination with _ and _.

A

First
NS3/4A protease inhibitors

PO

PegIFN and ribavirin
1

Anemia, fatigue, dysgeusia, nausea and headache

Low
PegIFN and ribavirin

34
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Telaprevir:

Mechanism of action:
_ generation _.

Drug availability:
Available _ twice daily

Clinical use:
It is used in combination with _ and _ for treatment of naïve and treatment experienced patients infected with HCV genotype _.

Side effects:
Telaprevir’s most common side effects are _ and . Rash does occur in up to 50% of patients. Fatalities have been reported in cases of severe _ so FDA issues a black BOX warning to discontinue all 3 drags (, _, and _) if rash occurs with systemic symptoms. Other side effects include (8). In addition to multiple drug-drug interactions.

Resistance:
(High / Low) barrier for resistance thus they need to be used in combination with _ and _

A

First
NS3/4A protease inhibitors

PO

PegIFN and ribavirin
1

rash and pruritis
rash
telaprevir, PegIFN and ribavirin
anemia, nausea, hemorrhoids, anorectal discomfort, dysgeusia, fatigue, vomiting and anal pruritis

Low
PegIFN and ribavirin

35
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Sofosbuvir:

Mechanism of action:
_ generation _. It is a _ analogue that inhibits the _ polymerase.

Drug availability:
_ form administered orally daily.

Clinical use:

Approved in 2013 for the treatment of patients with genotype _ HCV infection in combination with _ and _. In naïve patients the rate of SVR was up to 89% after 12 weeks of therapy.

It can also be used for other genotypes. Combination of _ and _ is the first all oral regimen approved for treatment of HCV genotype _ and _ with SVR as high as 97%. Duration of therapy is 12 weeks for genotype 2 and 24 weeks for genotype 3.

Side effects:
_ tolerated. No significant side effects.

Resistance:
Resistant variants exist in (vivo / vitro) but do not appear to have an impact in (vivo / vitro) on the susceptibility of sofosbuvir.

A

Second
polymerase inhibitor
nucleotide
NS5B

Pill

1
PegIFN and ribavirin

sofosbuvir and ribavirin
2 and 3

Well

vitro
vitro

36
Q

Mechanism of action of antivirals:
Treatment of Hepatitis C Virus (HCV):
Simeprevir:

Mechanism of action:
_ generation _ inhibitor.

Drug availability:
_ form administered orally once a day.

Clinical use:

Approved in 2013 for the treatment of patients with genotype _ HCV infection in combination with _ and _.

Combination _, _, and _ achieved SVR on up to 80 % of patients naïve to therapy or those who relapsed to prior combination therapy with PegIFN and ribavirin.

Side effects:
Well tolerated. Transient mild elevations of _ levels. _ and _ were reported as well.

Resistance:
Several mutations of _ are associated with reduced susceptibility to simeprevir.

A

Second
NS3/4A protease

Pill

1
PegIFN and ribavirin

simeprevir, PegIFN and ribavirin

bilirubin
Photosensitivity and rash

NS3/4A protease

37
Q

Mechanism of action of antivirals:
Treatment of Chronic Hepatitis B:

Treatment is only indicated for patients with persistently positive _ and _.

_ chronic carriers with _ liver enzymes and a _ liver biopsy should not be treated.

A

Hepatitis B surface Antigen (HBsAg)
chronic active hepatitis (liver inflammation)

Asymptomatic
normal
benign

38
Q

Mechanism of action of antivirals:
Treatment of Chronic Hepatitis B:
Lamivudine, Adefovir, Entecavir, Telbivudine, Emtricitabine and Tenofovir:

Mechanism of action:
These are _ analogues and suppress Hepatitis B viral replication by acting as chain terminators of HBV _ in _ of the genome.

Clinical use:
_ Hepatitis B infection.

Resistance:
The development of resistant mutations is common with _ use; 70% of HBV viruses are resistant to _ (YMDD mutation) within 4 years of treatment. Stopping these drugs may cause a flare-up of the hepatitis. Combination therapy with above drugs is being investigated and will likely be the treatment of choice in the near future, similar as in HIV

A

nucleoside/nucleotide
RNA
reverse transcription

Chronic active

prolonged
lamivudine

39
Q

Immunization:
Active immunization-Vaccines:

a. Live attenuated vaccines:

These vaccines contain a live-attenuated virus. They elicit an _ response but they are too weak to cause _. However, in immunocompromized hosts they can cause _ and are therefore not safe for these individuals.

b. Inactivated viruses or recombinant proteins. These are completely safe to be used in _ individuals.

A

immune
disease
illness

immunocompromized